{
    "id": "correct_subsidiary_00122_1",
    "rank": 67,
    "data": {
        "url": "https://investors.neuropace.com/corporate-governance/management",
        "read_more_link": "",
        "language": "en",
        "title": "Management",
        "top_image": "https://investors.neuropace.com/sites/g/files/knoqqb60136/files/favicon.png",
        "meta_img": "https://investors.neuropace.com/sites/g/files/knoqqb60136/files/favicon.png",
        "images": [
            "https://investors.neuropace.com/sites/g/files/knoqqb60136/themes/site/nir_pid3967/dist/images/NeuroPace-Logo-Horiz-rgb.png",
            "https://investors.neuropace.com/sites/g/files/knoqqb60136/themes/site/nir_pid3967/dist/images/NeuroPace-Logo-Horiz-rgb.png",
            "https://investors.neuropace.com/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2023/07/14/13-38-35/Joel-Becker-NeuroPace_waifu2x_photo_noise1_scale.jpg?itok=KTcpOw_Q",
            "https://investors.neuropace.com/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2021/03/16/12-32-45/marty-neuropace.jpg?itok=OcLcImlw",
            "https://investors.neuropace.com/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2021/03/16/12-33-43/Rebecca2.png?itok=bhi2zso0",
            "https://investors.neuropace.com/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2023/05/26/17-02-32/Kelley_Nicholas.png?itok=ldlZHv1i",
            "https://investors.neuropace.com/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2021/04/19/14-57-45/CSeale1.jpg?itok=vhLfJ6RT",
            "https://investors.neuropace.com/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2021/04/19/14-59-30/headshot-DSJ1.jpg?itok=vqj1tdaN",
            "https://investors.neuropace.com/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2023/07/14/13-43-57/2022-12-15_ELLUL_Stacey_Photo%20%28002%29.jpeg?itok=rcSV1Hn3",
            "https://investors.neuropace.com/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2024/04/18/18-00-14/DG_Photo.jpg?itok=rmohJmr4",
            "https://investors.neuropace.com/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2024/04/18/18-01-45/akin_S02_9675.jpg?itok=phNGSRv0"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "The Investor Relations website contains information about Neuropace's business for stockholders, potential investors, and financial analysts.",
        "meta_lang": "en",
        "meta_favicon": "/sites/g/files/knoqqb60136/files/favicon.png",
        "meta_site_name": "Neuropace",
        "canonical_link": "https://investors.neuropace.com/corporate-governance/management/",
        "text": "Joel D. Becker\n\nCEO and Board Member\n\nRead More\n\nJoel is a mission driven leader with more than twenty five years of experience in successfully building, growing and leading medical technology companies. He has a focus on executing growth strategies with operating discipline to exceed goals and develop market leadership in a patient first culture of strong values and ethics. Joel has extensive functional expertise and experience in General Management, Sales, Marketing, M&A, and Operations.\n\nPreviously Joel lead the $400M+ Cardiac Rhythm Management and Neuromodulation business as President for Integer Holdings LLC, a $1.2B publicly traded medical device contract development and manufacturing company, where he oversaw commercial execution with a focus on operational efficiencies and margin control. He also served as the President of the Americas Division for St. Jude Medical Inc., a $5.5B global medical device leader. In this role Joel lead the $3B commercial organizations for the electrophysiology, cardiology, structural heart, cardiac rhythm management and neuromodulation businesses in the Americas. In addition to a number of other leadership roles at St. Jude Medical, Joel also served as one of the founding members of the Atrial Fibrillation Division management team which he helped lead and grow to more than $700M in revenue.\n\nJoel holds a Masters in Business Administration degree from the Carlson School of Management at the University of Minnesota.\n\nMartha Morrell, MD\n\nChief Medical Officer\n\nRead More\n\nMartha Morrell, M.D. has served as our Chief Medical Officer since 2004. Dr. Morrell has also served as a Clinical Professor of Neurology at Stanford University since 2004. Dr. Morrell previously served as the Caitlin Tynan Doyle Professor of Clinical Neurology at Columbia University and Director of the Columbia Comprehensive Epilepsy Center at New York Presbyterian Hospital from 1998 to 2004. Prior to that, Dr. Morrell served on the faculty of the Stanford University School of Medicine and as the Director of the Stanford Comprehensive Epilepsy Center from 1990 to 1998. Dr. Morrell earned a B.A. from Barnard College and an M.D. from the Stanford University School of Medicine.\n\nRebecca Kuhn\n\nChief Financial Officer, Vice President, Finance and Administration, and Corporate Secretary.\n\nRead More\n\nRebecca Kuhn has served as our Chief Financial Officer and Vice President, Finance and Administration since 2000. From 1992 to 2000, Ms. Kuhn served in roles of increasing responsibility, most recently as Treasurer and Director of Finance at Heartport, Inc., a medical device company. Ms. Kuhn earned a B.S. in Business Administration from The Ohio State University and an M.B.A. from the Graduate School of Business at Stanford University.\n\nKelley Nicholas\n\nVice President of Sales\n\nRead More\n\nKelley Nicholas has served as our Vice President of Sales since May 2023. Ms. Nicholas previously served as the Global Vice President of Marketing and Commercial Operations at Hologic, a medical device company, from June 2021-February 2023, where she was responsible for leading all functions of marketing, commercial operations and training, professional education, and communications for the Breast and Skeletal Health Division. In this role Ms. Nicholas led the development of the 5-year business strategic plan and implementation of commercial strategies to drive growth and market expansion in new and existing businesses globally. From 2020-2021, Ms. Nicholas served as the Global Vice President of Commercial for Thermo Fisher Scientific, a medical device company, where she was responsible for leading a global commercial team and led the re-design of the go-to-market strategy. Prior to that, from 2014-2020, Ms. Nicholas served in sales leadership roles at Medtronic across various business units, inclusive of neurosurgery, cardiac and vascular surgery, and diabetes. From 2008-2014, Ms. Nicholas served in roles of increasing responsibility in sales leadership at Baxter, a medical device company, in their Biosurgery Business Unit. Mrs. Nicholas earned her B.S. in Health Science / Physical Therapy from the University of Missouri, Columbia, and her MBA from Washington University in St. Louis.\n\nCairn Seale\n\nVice President, Clinical Research\n\nRead More\n\nCairn Seale has served as our Vice President, Clinical Research since January 2021. Ms. Seale previously served in various roles of increasing responsibility, from Trial Manager to Senior Director of Clinical and Research since joining NeuroPace in 2002. Prior to that, Ms. Seale served as Manager of Clinical Research at the Stanford Epilepsy Center, from 1994 to2000 and at Columbia University Department of Neurology from 1998 to 2000. Ms. Seale earned a B.A. from Stanford University and an M.S. from Stanford University School of Medicine.\n\nDylan St. John\n\nChief, Operations and Development\n\nRead More\n\nDylan St. John has served as our Chief, Operations and Development since May 2024, prior to which, Mr. St. John served in various roles since joining NeuroPace in 2013, most recently as our Vice President, Manufacturing and Commercial Operations. Mr. St. John previously served as New Product Introduction (NPI) Program Manager at Calibra Medical, a Johnson & Johnson company, a medical device company, from 2012 to 2013. Prior to that, Mr. St. John served as Sr. Manager of Global Packaging and Labeling at LifeScan, Inc., a Johnson & Johnson company, a medical device company, from 2007 to 2012. Mr. St. John earned a B.S. from San Jose State University.\n\nStacey Ellul\n\nVice President, Quality & Regulatory Affairs\n\nRead More\n\nStacey Ellul has served as our Vice President, Quality & Regulatory Affairs since December 2022. Ms. Ellul previously served as Vice President of Regulatory Science & Communications for the Diabetes Operating Unit of Medtronic, a medical device company, from 2019 to 2022. Since 2003, Ms. Ellul has held positions of increasing responsibility in medical device companies in both regulatory, clinical/ medical affairs, and quality. Prior to joining the medical device industry Ms. Ellul was a critical care nurse. She earned a DipApp Sc (Nursing), GradDip (Management) and an MBA from the University of South Australia, Australia.\n\nDavid Greene\n\nVice President, Clinical Engineering\n\nRead More\n\nDavid Greene has served as our Vice President, Clinical Engineering since March 2024, prior to which he served as Executive Director of Clinical Engineering and Director of Field Clinical Engineering and was part of the core team that developed the RNS System. Prior to NeuroPace, Mr. Greene was Director of Field Clinical Engineering at St. Jude Medical from 1997-2000, and worked as a Field Clinical Engineer at Ventritex, Inc. from 1992-1997. Mr. Greene has a B.S. in Mechanical Engineering from the University of Florida and a Certificate in Regulatory Affairs from Ivy Tech."
    }
}